Physician profile
Sonja Gerald
NPI 1700197167
$3,405.74
in general payments reported to CMS, 2019-2025
24 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.04 · 2020: $110 · 2021: $340 · 2022: $653 · 2023: $556 · 2024: $936 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $753.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $438.67 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $317.24 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $281.40 | 2021-2025 | |
| Abbvie INC. | $279.07 | 2021-2025 | |
| Exact Sciences Corporation | $249.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.39 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $153.68 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $121.71 | 2022-2024 | |
| Amgen INC. | $119.21 | 2020-2024 | Repatha, Otezla |
| Corcept Therapeutics | $83.84 | 2025 | Korlym |
| Horizon Therapeutics Plc | $72.70 | 2022 | |
| Abbott Laboratories | $59.48 | 2022-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $51.83 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $48.29 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $34.35 | 2022 | |
| Madrigal Pharmaceuticals | $33.81 | 2025 | Rezdiffra |
| Sanofi-Aventis U.S. LLC | $30.26 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $26.43 | 2021 | |
| Dexcom, INC. | $25.94 | 2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $22.29 | 2024 | Aptima |
| Globus Medical, INC. | $21.70 | 2025 | Senza |
| Mylan Specialty L.P. | $14.28 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonja Gerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.